# MAFB

## Overview
The MAFB gene encodes the MAF bZIP transcription factor B, a member of the large Maf family of transcription factors characterized by a basic leucine zipper (bZip) domain. This domain is essential for the protein's ability to bind DNA and form dimers, which are crucial for its function as a transcription factor (Kataoka1994MafB). MAFB plays a significant role in various biological processes, including cellular differentiation, immune response, and kidney function. It is involved in the differentiation of pancreatic β-cells and monocytes, as well as the maintenance of podocyte structure in the kidneys (Gemelli2006Virally; Russell2020Loss; Morito2023Podocytespecific). Clinically, mutations in the MAFB gene are linked to several disorders, such as multicentric carpotarsal osteolysis syndrome, focal segmental glomerulosclerosis, and Duane retraction syndrome, highlighting its critical role in human health and disease (Drovandi2022Multicentric; Park2016Loss; Usui2020Transcription).

## Structure
The MAFB protein is a transcription factor characterized by a basic leucine zipper (bZip) domain, which is crucial for its DNA-binding and dimerization capabilities (Kataoka1994MafB). The primary structure of MAFB consists of 311 amino acids, with significant homology to other Maf family proteins, particularly in the bZip domain (Kataoka1994MafB). This domain facilitates the formation of homodimers and heterodimers, allowing MAFB to bind specifically to Maf-recognition elements (MAREs) (Kataoka1994MafB).

The secondary structure includes the bZip motif, which is essential for its function and is involved in forming alpha helices that enable dimerization (Kataoka1994MafB). The tertiary structure involves the three-dimensional folding necessary for its interaction with DNA and other proteins, although specific details on the overall folding pattern are not provided in the context.

In terms of quaternary structure, MAFB can form homodimers and heterodimers with proteins like v-Maf and Fos, but not with Jun (Kataoka1994MafB). Post-translational modifications, such as phosphorylation, play a role in regulating MAFB's stability and degradation, particularly through the ubiquitin-proteasome pathway (Tanahashi2010MafB).

## Function
The MAFB gene encodes a transcription factor that plays a critical role in various cellular differentiation processes in healthy human cells. MAFB is involved in the differentiation of human embryonic stem cells into pancreatic β-like cells, where it is essential for maintaining β-cell identity and function. Its absence leads to altered hormone expression, favoring somatostatin and pancreatic polypeptide production over insulin and glucagon, which are crucial for glucose regulation (Russell2020Loss).

In the immune system, MAFB is a key regulator of monocyte and macrophage differentiation. It promotes the commitment of hematopoietic stem cells to the monocyte lineage, upregulating macrophage-related transcription factors and inhibiting erythroid differentiation (Gemelli2006Virally). MAFB also regulates the expression of complement component C1q in macrophages, which is essential for efferocytosis, a process that prevents autoimmune diseases (Tran2017MafB).

In the kidneys, MAFB is expressed in podocytes, where it is crucial for maintaining podocyte structure and function. It regulates proteins associated with the slit diaphragm, such as Nephrin, and influences pathways that protect podocytes from oxidative stress and apoptosis (Morito2023Podocytespecific).

## Clinical Significance
Mutations in the MAFB gene are associated with several human diseases, notably multicentric carpotarsal osteolysis (MCTO) syndrome, focal segmental glomerulosclerosis (FSGS), and Duane retraction syndrome (DRS). MCTO is a rare genetic disorder characterized by progressive osteolysis, particularly affecting the carpal and tarsal bones, and is frequently accompanied by nephropathy, leading to kidney failure in some cases (Drovandi2022Multicentric). MAFB mutations in MCTO often cluster within a specific region of the gene, resulting in a wide range of phenotypical heterogeneity (Drovandi2022Multicentric).

In the context of FSGS, MAFB mutations lead to impaired podocyte function, contributing to proteinuria and renal failure. Studies have shown that decreased MAFB expression in podocytes is linked to the development of FSGS, highlighting its protective role in kidney function (Usui2020Transcription). 

MAFB mutations are also implicated in DRS, a congenital eye-movement disorder. These mutations can cause aberrant innervation of extraocular muscles and defects in cranial nerve development, sometimes accompanied by hearing loss (Park2016Loss). The gene's role in these conditions underscores its importance in normal developmental processes and disease pathogenesis.

## Interactions
MAFB, a member of the large Maf transcription factors, participates in various protein-protein interactions that influence its function as a transcription factor. MAFB can form homodimers and heterodimers with other proteins such as v-Maf and Fos through its leucine zipper motif. However, it does not associate with Jun or small Maf proteins like MafK, MafF, and MafG (Kataoka1994MafB).

MAFB also interacts with the HTLV-1 basic leucine-zipper factor (HBZ). This interaction occurs through the bZIP domains of both proteins, forming heterodimers that affect transcriptional activity. HBZ suppresses MAFB-mediated transcription through Maf recognition elements (MAREs) and promotes MAFB degradation via a proteasome-dependent pathway (Ohshima2010HTLV‐1).

Additionally, MAFB interacts with Ets-1, a transcription factor involved in erythroid differentiation. MAFB acts as a repressor of Ets-1, inhibiting its transactivation function and thereby affecting erythroid differentiation. This interaction does not require MAFB's DNA binding, indicating a specific protein-protein interaction mechanism (Sieweke1996MafB).


## References


[1. (Gemelli2006Virally) C Gemelli, M Montanari, E Tenedini, T Zanocco Marani, T Vignudelli, M Siena, R Zini, S Salati, E Tagliafico, R Manfredini, A Grande, and S Ferrari. Virally mediated mafb transduction induces the monocyte commitment of human cd34+ hematopoietic stem/progenitor cells. Cell Death &amp; Differentiation, 13(10):1686–1696, February 2006. URL: http://dx.doi.org/10.1038/sj.cdd.4401860, doi:10.1038/sj.cdd.4401860. This article has 57 citations.](https://doi.org/10.1038/sj.cdd.4401860)

[2. (Morito2023Podocytespecific) Naoki Morito, Toshiaki Usui, Shun Ishibashi, and Kunihiro Yamagata. Podocyte-specific transcription factors: could mafb become a therapeutic target for kidney disease? Internal Medicine, 62(1):11–19, January 2023. URL: http://dx.doi.org/10.2169/internalmedicine.9336-22, doi:10.2169/internalmedicine.9336-22. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.2169/internalmedicine.9336-22)

[3. (Kataoka1994MafB) Kohsuke Kataoka, Kosaku T. Fujiwara, Makoto Noda, and Makoto Nishizawa. Mafb, a new maf family transcription activator that can associate with maf and fos but not with jun. Molecular and Cellular Biology, 14(11):7581–7591, November 1994. URL: http://dx.doi.org/10.1128/mcb.14.11.7581-7591.1994, doi:10.1128/mcb.14.11.7581-7591.1994. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.14.11.7581-7591.1994)

[4. (Ohshima2010HTLV‐1) Takayuki Ohshima, Risa Mukai, Norie Nakahara, Jun Matsumoto, Osamu Isono, Yusuke Kobayashi, Satoru Takahashi, and Kunitada Shimotohno. Htlv‐1 basic leucine‐zipper factor, hbz, interacts with mafb and suppresses transcription through a maf recognition element. Journal of Cellular Biochemistry, 111(1):187–194, August 2010. URL: http://dx.doi.org/10.1002/jcb.22687, doi:10.1002/jcb.22687. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.22687)

[5. (Tran2017MafB) Mai Thi Nhu Tran, Michito Hamada, Hyojung Jeon, Risako Shiraishi, Keigo Asano, Motochika Hattori, Megumi Nakamura, Yuki Imamura, Yuki Tsunakawa, Risa Fujii, Toshiaki Usui, Kaushalya Kulathunga, Christina-Sylvia Andrea, Ryusuke Koshida, Risa Kamei, Yurina Matsunaga, Makoto Kobayashi, Hisashi Oishi, Takashi Kudo, and Satoru Takahashi. Mafb is a critical regulator of complement component c1q. Nature Communications, November 2017. URL: http://dx.doi.org/10.1038/s41467-017-01711-0, doi:10.1038/s41467-017-01711-0. This article has 63 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-017-01711-0)

[6. (Tanahashi2010MafB) Hiroshi Tanahashi, Keiji Kito, Takashi Ito, and Katsuji Yoshioka. Mafb protein stability is regulated by the jnk and ubiquitin–proteasome pathways. Archives of Biochemistry and Biophysics, 494(1):94–100, February 2010. URL: http://dx.doi.org/10.1016/j.abb.2009.11.018, doi:10.1016/j.abb.2009.11.018. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.abb.2009.11.018)

[7. (Drovandi2022Multicentric) Stefania Drovandi, Francesca Lugani, Olivia Boyer, Edoardo La Porta, Paolo Giordano, Aurélie Hummel, Bertrand Knebelmann, Joséphine Cornet, Genevieve Baujat, Beata S. Lipska-Ziętkiewicz, Gian Marco Ghiggeri, Gianluca Caridi, and Andrea Angeletti. Multicentric carpotarsal osteolysis syndrome associated nephropathy: novel variants of mafb gene and literature review. Journal of Clinical Medicine, 11(15):4423, July 2022. URL: http://dx.doi.org/10.3390/jcm11154423, doi:10.3390/jcm11154423. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/jcm11154423)

[8. (Park2016Loss) Jong G. Park, Max A. Tischfield, Alicia A. Nugent, Long Cheng, Silvio Alessandro Di Gioia, Wai-Man Chan, Gail Maconachie, Thomas M. Bosley, C. Gail Summers, David G. Hunter, Caroline D. Robson, Irene Gottlob, and Elizabeth C. Engle. Loss of mafb function in humans and mice causes duane syndrome, aberrant extraocular muscle innervation, and inner-ear defects. The American Journal of Human Genetics, 98(6):1220–1227, June 2016. URL: http://dx.doi.org/10.1016/j.ajhg.2016.03.023, doi:10.1016/j.ajhg.2016.03.023. This article has 60 citations.](https://doi.org/10.1016/j.ajhg.2016.03.023)

[9. (Usui2020Transcription) Toshiaki Usui, Naoki Morito, Hossam H. Shawki, Yoshinori Sato, Hiroyasu Tsukaguchi, Michito Hamada, Hyojung Jeon, Manoj Kumar Yadav, Akihiro Kuno, Yuki Tsunakawa, Risa Okada, Takaaki Ojima, Maho Kanai, Keigo Asano, Yuki Imamura, Ryusuke Koshida, Keigyou Yoh, Joichi Usui, Hideki Yokoi, Masato Kasahara, Ashio Yoshimura, Masafumi Muratani, Takashi Kudo, Hisashi Oishi, Kunihiro Yamagata, and Satoru Takahashi. Transcription factor mafb in podocytes protects against the development of focal segmental glomerulosclerosis. Kidney International, 98(2):391–403, August 2020. URL: http://dx.doi.org/10.1016/j.kint.2020.02.038, doi:10.1016/j.kint.2020.02.038. This article has 24 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.kint.2020.02.038)

[10. (Russell2020Loss) Ronan Russell, Phichitpol P. Carnese, Thomas G. Hennings, Emily M. Walker, Holger A. Russ, Jennifer S. Liu, Simone Giacometti, Roland Stein, and Matthias Hebrok. Loss of the transcription factor mafb limits β-cell derivation from human pscs. Nature Communications, June 2020. URL: http://dx.doi.org/10.1038/s41467-020-16550-9, doi:10.1038/s41467-020-16550-9. This article has 38 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-16550-9)

[11. (Sieweke1996MafB) Michael H Sieweke, Hildegard Tekotte, Jonathan Frampton, and Thomas Graf. Mafb is an interaction partner and repressor of ets-1 that inhibits erythroid differentiation. Cell, 85(1):49–60, April 1996. URL: http://dx.doi.org/10.1016/s0092-8674(00)81081-8, doi:10.1016/s0092-8674(00)81081-8. This article has 238 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(00)81081-8)